SEC Form 4 · accession 0001209191-18-043879
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elaine Castellanos
Officer — Principal Accounting Officer
Period of report
Jul 23, 2018
Accepted (ET)
Jul 25, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF2 | Jul 23, 2018 | S | 7,196 | $50.80 | D | 140 | D | |
| Class A common stockF3 | Jul 23, 2018 | S | 140 | $51.48 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016 and amended on September 15, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $50.33 to $51.31. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $51.45 to $51.485. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.